FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#1 | |||
|
||||
Senior Member
|
Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline
Tamar Goren 1*, Liat Adar 1, Nissim Sasson 1, and Yoni M. Weiss 1 1 Teva Pharmaceutical Industries Ltd * To whom correspondence should be addressed. E-mail: tamar.goren@teva.com.il. Abstract Rasagiline is a selective, monoamine oxidase (MAO)-B inhibitor indicated for treatment of Parkinson’s disease. This double-blind, placebo-controlled study determined the tyramine sensitivity factor (TSF) and degree of MAO-A inhibition (ie, reduction in plasma dihydroxyphenylglycol) in healthy volunteers who received phenelzine (15 mg, 3 times daily; positive control), selegiline (5 mg, twice daily), or rasagiline (1-6 mg, once daily) for 14 days or rasagiline 2 mg/d for 30 days... Plasma dihydroxyphenylglycol concentrations suggested that rasagiline 1 mg/d had no effect, whereas rasagiline 2 mg/d had only minimal effect. In contrast, rasagiline 4 and 6 mg/d reduced dihydroxyphenylglycol to a degree approaching that achieved by the positive control phenelzine. Results demonstrate that rasagiline selectively inhibits MAO-B and is not associated with increased tyramine sensitivity at the indicated dose (1 mg/d). These data allowed removal of dietary tyramine restriction from rasagiline US labeling. http://jcp.sagepub.com/cgi/content/a...270010369674v1
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
![]() |
![]() |
![]() |
#2 | ||
|
|||
New Member
|
i was taking 0.05 once a day pill 3 x a day for a week. this was by mistake, will it hurt me
|
||
![]() |
![]() |
![]() |
#3 | |||
|
||||
Senior Member
|
I hope everything has resolved without adverse effects? are you okay now, having decreased the doseage to the normal 1 mgm/day? the one problem that jumped out at me was that with an increased doseage, might change the MAO B selectivity to include some MAO A activity--necessitating elimination of tyramine in diet. (ie the "dreaded cheese effect"). since 2 mg/day is also considered a "within normal limits" doseaage, would not think one would experience the other effects of overdoseage with just 1 week of medication. though that's not a professional opinion, and as my husband often reminds me "is worth what you are paying me for it".
Mostly, just wanted to check in to see how you are faring?
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
![]() |
![]() |
Reply |
|
|
![]() |
||||
Thread | Forum | |||
selective IgA deficiency | Gluten Sensitivity / Celiac Disease | |||
MAO B inhibition | Parkinson's Disease | |||
Microglial inhibition - quenching a slow burn | Parkinson's Disease | |||
Selective Dorsal Rhizotomy | Children's Health | |||
inhibition of either COX-1/COX-2 ---> neuroprotection against MPTP-toxicity | Parkinson's Disease |